CD47 and hematologic disorder: As a dual-functioning soluble decoy receptor with the CD47-binding domain of SIRPα fused to an IgG1 Fc region, TTI-621 had been applied intravenously for hematological malignancies and intratumorally for solid tumors and mycosis fungoides [53].